52565-56-7

Basic information

• Product Name: 4-PHENYLPYRIDINE-2-CARBOXYLIC ACID
• Synonyms: 4-PHENYLPYRIDINE-2-CARBOXYLIC ACID;4-PHENYLPICOLINIC ACID;4-PHENYL-2-PYRIDINECARBOXYLIC ACID;4-Phenylpyridine-2-carboxylicacid97%
• CAS NO: 52565-56-7
• Molecular Formula: C₁₂H₉NO₂
• Molecular Weight: 199.21
• EINECS: 1806241-263-5
• Product Categories: Carboxylic Acids;Pyridines;Carboxylic Acids
• Mol File: 52565-56-7.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 405 °C at 760 mmHg
• Flash Point: 198.7 °C
• Appearance: /
• Density: 1.241 g/cm³
• Vapor Pressure: 2.76E-07mmHg at 25°C
• Refractive Index: 1.613
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 0.98±0.50(Predicted)
• CAS DataBase Reference: 4-PHENYLPYRIDINE-2-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-PHENYLPYRIDINE-2-CARBOXYLIC ACID(52565-56-7)
• EPA Substance Registry System: 4-PHENYLPYRIDINE-2-CARBOXYLIC ACID(52565-56-7)

Safety Data

• Hazardous Substances Data: 52565-56-7(Hazardous Substances Data)

Usage

General Description

4-Phenylpyridine-2-carboxylic acid is a chemical compound with the formula C12H9NO2. It is a carboxylic acid derivative of pyridine and contains a phenyl group attached to the 4-position of the pyridine ring. 4-PHENYLPYRIDINE-2-CARBOXYLIC ACID is used in the pharmaceutical industry as a building block in the synthesis of various pharmaceuticals and agrochemicals. It has also been studied for its potential biological activities, including its antibacterial and antifungal properties. Additionally, 4-phenylpyridine-2-carboxylic acid is used as a reagent in organic synthesis to introduce the 4-pyridyl carboxylic acid group into various molecules.

InChI:InChI=1/C12H9NO2/c14-12(15)11-8-10(6-7-13-11)9-4-2-1-3-5-9/h1-8H,(H,14,15)

Upstream product

• 54151-74-5 2-bromo-4-phenylpyridine 
• 30766-03-1 4-bromo-2-picolinic acid 
• 98-80-6 phenylboronic acid 
• 1019927-13-9 1-oxy-4-phenyl-pyridine-2-carbonitrile 

Downstream Products

• 906089-68-7 4-phenyl-pyridine-2-carboxamide, N-[(1S,2R)-1-[[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]amino]carbonyl]-2-hydroxypropyl] 
• 1397226-47-9 C₂₀H₁₇N₃O₂S 

Relevant articles and documents

QUINOLINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS

Disclosed are imidazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure (I) and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein R1, X, Y1, Y2, Y3 and Z are as described herein. In certain embodiments, a compound disclosed herein inhibits a cellular TAM receptor, and can be used to treat disease mediated by or involving the TAM receptor family.

Rare aryl amide structure heterocyclic compound and its preparation method and application

The invention discloses a biaryl amide structure containing heterocyclopyrimidine compound as well as a geometrical isomer, a pharmaceutically acceptable salt, a hydrate, a solvate or a prodrug and a preparation method of the heterocyclopyrimidine compound. The biaryl amide structure containing heterocyclopyrimidine compound as well as the pharmaceutically acceptable salt, the hydrate or the solvate of the heterocyclopyrimidine compound are taken as active components and mixed with a pharmaceutically acceptable carrier or excipient for preparation of composition and clinically acceptable dosage forms. The invention further discloses applications of the compound to preparation of drugs for treating and/or preventing hyperplastic diseases, preparation of drugs for treating and/or preventing cancer and preparation of drugs for treating and/or preventing prostate cancer, lung cancer and liver cancer.

Design, synthesis, and docking studies of phenylpicolinamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors

Four series of phenylpicolinamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety (12a-e, 13a-f, 14a-f and 15a-i) were designed, synthesized and evaluated for the IC50 values against three cancer cell lines (A549, PC-3 and MCF-7) and c-Met kinase. Five selected compounds (13b, 15b, 15d, 15e and 15f) were further evaluated for the activity against HepG2 and Hela cell lines. Eighteen of the compounds showed excellent cytotoxicity activity and selectivity with the IC50 valuables in single-digit μM to nanomole range. Seven of them are equal to more active than positive control Foretinib against one or more cell lines. The most promising compound 15f showed superior activity to Foretinib, with the IC50 values of 1.04 ± 0.11 μM, 0.02 ± 0.01 μM and 9.11 ± 0.55 μM against A549, PC-3 and MCF-7 cell lines, which were 0.62 to 19.5 times more active than Foretinib (IC50 values: 0.64 ± 0.26 μM, 0.39 ± 0.11 μM, 9.47 ± 0.22 μM), respectively. Structure-activity relationships (SARs) and docking studies indicated that replacement of quinoline nucleus of the previous active compounds with 1H-pyrrolo[2,3-b]pyridine moiety maintained even improved the potent cytotoxic activity. The results suggested that the introduction of fluoro atoms to the aminophenoxy part of target compounds or the phenyl group of pyrimidine substituted on C-4 position was benefit for the activity.